en
FR DE

Priority Research Axes

The Cancéropôle has 4 priority research axes:

Priority Research axis A: Health indicators-Epidemiology-Human and Social Sciences

The priority research axis A includes on the one hand research characterizing better detection of cancer risk factors, quality of life and health indicators. On the other hand it measures the impact of patient care path in prevention, diagnosis and care. This axis implies multidisciplinary teams and expertise platforms such as the Quality of Life platform launched by the Cancéropôle. For more information

 

Priority Research axis B: Translational Research- Biomarkers, imaging technologies and early phase trials

The priority research axis B aims to develop translational research towards the patient involving scientists and clinicians. Research projects on the comprehension of the response to therapy, the discovery of new biomarkers, new imaging technologies or agents are developed within this axis. Cellular and/or animal models as well as clinical trials are used to answer the biological and clinical questions. The objective is to determine the patient’s precise situation in order to offer him/her the best care. For more information

 

Priority Research axis C: Viral infection and Cancer

The research projects in the axis C are centered on the study of the mechanisms linked to infectious agents and in particular the papilloma virus, that lead to a cellular deregulation and consequently to cancer. The results obtained aim to implement a new prevention policy together with, for example, the development of new diagnostic tests or a vaccine. They allow also the development of new therapy or prognosis tools. For more information

 

Priority Research axis D: Immunity and Cancer

This priority research axis is based on immunotherapy in cancer. Studies are conducted on the development of new immunotherapy based on the molecular signaling involved in the regulation of the host/tumor interaction, allogenic cellular therapies or new vaccine strategy. The changes in the immune response during chemotherapy are also studied in order to develop new chemotherapy strategies with reduced immunosuppressive effect. For more information

 

Newsletter

The newsletter keeps you informed about the Cancéropôle's news and its upcoming events.

Subscribe Download

Forum of the Cancéropôle

More

OncoTrans Conference

More